Cyclosporine renal dysfunction

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S243-S247

  Vitko S ^a   Viklicky O ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ENALAPRIL; ENDOTHELIN 1; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN; VASCULOTROPIN;

ARTERY CONSTRICTION; ARTICLE; CELL VACUOLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ACIDOSIS; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; OLIGURIA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM INTAKE; SYMPATHETIC NERVE; UPREGULATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 19244381999     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.033     Document Type: Article

References (35)

1. Bennett W.M., De Mattos A., Meyer M.M., et al. Chronic cyclosporine nephropathy. The Achille's heel of immunosuppressive therapy. Kidney Int. 50:1996;1089.
2. Feutren G., Mihatsch M.J. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med. 326:1992;1654.
3. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 311:1984;699.
4. Myers B.D., Newton L., Boshkos C., et al. Chronic injury of human microvessels with low-dose cyclosporine therapy. Transplantation. 46:1988;694.
5. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of nonrenal origin. N Engl J Med. 349:2003;931.
6. Schechter P. Acute tubular necrosis following high-dose cyclosporine A therapy. Eur J Clin Pharmacol. 49:1996;521.
7. Davies D.R. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation. 69:2000;SS11.
8. Olyaei A.J., de Mattos A.M., Bennett W.M. Immunosuppressant-induced nephropathy pathophysiology, incidence and management. Drug Saf. 21:1999;471.
9. Shihab F.S., Andoh T.F., Tanner A.M., et al. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis. 30:1997;71.
10. Mezzano S.A., Ruiz-Ortega M., Egido J. Angiotensin II and renal fibrosis. Hypertension. 38:2001;635.
11. Lassila M., Finckenberg P., Pere A.K., et al. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol. 130:2000;1339.
12. Khanna A.K., Cairns V.R., Becker C.G., et al. Transforming growth factor (TGF)-beta mimics and anti-TGF beta antibody abrogates the in vivo effects of cyclosporine demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation. 67:1999;882.
13. Shin G.T., Khanna A., Ding R., et al. In vivo expression of transforming growth factor-beta1 in humans stimulation by cyclosporine. Transplantation. 65:1998;313.
14. Islam M., Burke J.F. Jr, McGowan T.A., et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int. 59:2001;498.
15. Baan C.C., Balk A.H., Holweg C.T., et al. Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant. 19:2000;866.
16. Shihab F.S., Bennett W.M., Yi H., et al. Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity. Transplantation. 72:2001;164.
17. Shihab F.S., Bennett W.M., Isaac J., et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int. 63:2003;522.
18. Shihab F.S., Bennett W.M., Isaac J., et al. Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity. Kidney Int. 62:2002;422.
19. Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62:2002;311.
20. Meier-Kriesche H.U., Baliga R., Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 75:2003;1291.
21. Kasiske B.L., Chakerra H.A., Luis T.A. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 10:2000;1910.
22. Hueso M., Bover J., Seron D., et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation. 66:1998;1727.
23. Weir M.R., Ward M.T., Blahut S.A. Long-term impact of discontinued or reduced calcineurin binhibitor therapy in patients with chronic allograft nephropathy. Kidney Int. 59:2001;1567.
24. Kahan B.D., Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection a randomized multicenter study. Lancet. 356:2000;194.
25. McDonald A.S., Rapamune Global Study Group. A worldwhile, phase UIII, randomized controlled safety and efficacy of a sirolimus/cyclosporine regimen for prevention of acute rejekction in recipients of primary mismatched renal allografts. Transplantation. 71:2001;271.
26. Vítko S., Margreiter R., Weimar W., et al. International, double-blind, parallel-group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral® and steroids. Am J Transplant. 1:(Suppl 1):2001;474. (Abstract 1337).
27. Babbolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimisation or elimination at six months in de novo renal allograft recipients. Transplantation. 75:2003;1404.
28. Vítko S., Welchel J., Eris J., et al. Excellent graft function in de novo kidney transplant recipients treated with everolimus, reduced dose Neoral® and Simulect® 6 months analysis. Am J Transplant. 3:(Suppl 5):2003;311. (Abstract 625).
29. Tedesco H., Pascual J., Civati G., et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral® in de novo kidney transplant recipients 6 months analysis. Am J Transplant. 3:(Suppl 5):2003;462. (Abstract 1210).
30. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 76:2003;364.
31. Ruiz J.C., Campistol J.M., Mota A., et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc. 35:2003;1669.
32. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 67:1999;1036.
33. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 69:2000;1252.
34. Vincenti F., Ramos E., Brattstrom C. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 71:2001;1282.
35. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 74:2003;1070.